You do not have permission to view this document: [5943448]!
Study Start Date: 07/01/2010
Study End Date: 07/01/2011
We recently discovered that interleukin-6 (IL-6) is markedly upregulated in the intestinal mucosa of cats with IBD and alimentary lymphoma. We would now like to evaluate the serum of cats with enteric disease for non-invasive markers of enteric disease, including IL-6. We are seeking serum samples from cats with chronic GI signs that have been definitively diagnosed by histologic biopsy with either IBD OR alimentary lymphoma.
Study Design:
Prospective case-control study
Sample Size:
50 IBD cats, 50 lymphoma
Inclusion Criteria:
- Adult cats of any breed with a recent diagnosis on histology of IBD or intestinal lymphoma.
- Not receiving any chemotherapy, anti-inflammatory or other immunosuppressive medication.
- No known concurrent disease, e.g., pancreatic, hepatic, or renal disease, hyperthyroidism.
- Known FeLV/FIV status.
Exclusion Criteria:
- Presumptive diagnosis of IBD or lymphoma without histologic confirmation.
- Cats previously diagnosed and now in remission
Study Controls:
Healthy cats that have already undergone intestinal biopsy for an earlier study will be used as historical controls.
Study Endpoints:
n/a
Samples:
SEPARATED SERUM 1-2 mls. Stored refrigerated or frozen and shipped on an ice pack.
Costs/Reimbursements:
None
You do not have permission to view this document: [5943471]!
Full Disclosure information:
- The study is funded by an intramural institutional grant.
- The investigator does not have a conflict of interest.
- The study will be published if results are negative.
- The study will be reported on VIN.
- The authors will acknowledge VIN if the study is published.